Laura Aschenbrenner

Medicine · Health Sciences

10h-index793citations38works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(19), Monoclonal and Polyclonal Antibodies Research(19), Synthesis and Biological Evaluation(17), Influenza Virus Research Studies(7), HER2/EGFR in Cancer Research(5)

Publications38 total

Data from RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
2023Open Access
Tables and Methods from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S3 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S2 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S1 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S7 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S3 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Tables and Methods from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S4 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S1 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S4 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S2 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Supplemetal Figures 1 and 2 from RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
2023Open Access
Figure S5 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Data from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S6 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Figure S5 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Supplemetal Figures 1 and 2 from RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
2023Open Access
Figure S7 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
Data from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Pavel Strop(26), Kathy Delaria(24), Russell G. Dushin(24), Bora Han(24), Arvind Rajpal(24), Kevin C. Lindquist(21), Thomas Van Blarcom(21), Javier Chaparro‐Riggers(21), Bernard S. Buetow(20), Siler H. Panowski(19), Tracy C. Kuo(19), Amy Chen(19), Cris Kamperschroer(19), Edward Pascua(19), Santiago Farias(19), Marjorie Bateman(19), Sherman M. Chin(19), Yik A. Yeung(19), Allison G. Chunyk(19), Michael Mirsky(19)